Azitra (AZTR) Free Cash Flow (2022 - 2026)
Azitra (AZTR) posted Free Cash Flow of -$2.5 million for Q1 2026, up 13.4% on a QoQ basis from -$2.9 million in Q4 2025, and up 18.87% year-over-year from -$2.1 million in Q1 2025.
Azitra (AZTR) Free Cash Flow (2022 - 2026) Analysis & Trends
Azitra's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$2.5 million for Q1 2026.
- Quarterly Free Cash Flow rose 18.87% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.6 million (down 3.91% YoY) and the FY2025 annual result came in at -$11.2 million, down 10.12% from the prior year.
- Free Cash Flow was -$2.5 million for Q1 2026 at Azitra, up from -$2.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.3 million in Q1 2023 and bottomed at -$3.1 million in Q1 2025.
- A 5-year average of -$2.4 million and a median of -$2.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 129.01% — and 2026, when it advanced 18.87%.
- Azitra's Free Cash Flow stood at -$2.2 million in 2022, then slipped by 16.65% to -$2.6 million in 2023, then retreated by 1.33% to -$2.6 million in 2024, then decreased by 11.27% to -$2.9 million in 2025, then grew by 13.4% to -$2.5 million in 2026.
- Business Quant data shows AZTR's Free Cash Flow at -$2.5 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | -2.49 Mn |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 158.09 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 1.29 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | 848.30 Mn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 48.67 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | -354.95 Mn |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | -2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Jun 30, 2025 | -2.83 Mn |
| Jun 30, 2025 | -2.83 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.48 Mn |
| Sep 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Dec 31, 2023 | -2.55 Mn |
| Dec 31, 2023 | -2.55 Mn |